Sign In

Login

Password

Forgot Password ? Sign Up

نافاموستات (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "نافاموستات" in Persian language version.

refsWebsite
Global rank Persian rank
7nih.gov
4th place
5th place
5doi.org
2nd place
2nd place
1semanticscholar.org
11th place
52nd place
1archive.org
6th place
9th place

archive.org

doi.org

  • Al-Horani RA, Desai UR (November 2014). "Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders". Medicinal Research Reviews. 34 (6): 1168–216. doi:10.1002/med.21315. PMC 8788159. PMID 24659483. S2CID 22631056.
  • Chen X, Xu Z, Zeng S, Wang X, Liu W, Qian L, et al. (2019). "The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications". Frontiers in Oncology. 9: 852. doi:10.3389/fonc.2019.00852. PMC 6733886. PMID 31552177.
  • Sadahiro T, Yuzawa H, Kimura T, Oguchi M, Morito T, Mizushima S, Hirose Y (2018). "Current Practices in Acute Blood Purification Therapy in Japan and Topics for Further Study". Contributions to Nephrology. 196: 209–214. doi:10.1159/000485724. ISBN 978-3-318-06297-7. PMID 30041229.
  • Ramjee, M, Henderson, IJ, Sheila McLoughlin, SB & Padova, A (June 2000). "The kinetic and structural characterization of the reaction of nafamostat with bovine pancreatic trypsin". Thrombosis Research. 98 (6): 559–569. doi:10.1016/s0049-3848(00)00206-1. PMID 10899355.{{cite journal}}: نگهداری یادکرد:استفاده از پارامتر نویسندگان (link)
  • Ramjee, M & Patel, S (July 2017). "Continuous-flow injection microfluidic thrombin assays: The effect of binding kinetics on observed enzyme inhibition". Analytical Biochemistry. 528: 38–46. doi:10.1016/j.ab.2017.04.016. PMID 28456636.{{cite journal}}: نگهداری یادکرد:استفاده از پارامتر نویسندگان (link)

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Al-Horani RA, Desai UR (November 2014). "Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders". Medicinal Research Reviews. 34 (6): 1168–216. doi:10.1002/med.21315. PMC 8788159. PMID 24659483. S2CID 22631056.
  • Chen X, Xu Z, Zeng S, Wang X, Liu W, Qian L, et al. (2019). "The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications". Frontiers in Oncology. 9: 852. doi:10.3389/fonc.2019.00852. PMC 6733886. PMID 31552177.
  • Sadahiro T, Yuzawa H, Kimura T, Oguchi M, Morito T, Mizushima S, Hirose Y (2018). "Current Practices in Acute Blood Purification Therapy in Japan and Topics for Further Study". Contributions to Nephrology. 196: 209–214. doi:10.1159/000485724. ISBN 978-3-318-06297-7. PMID 30041229.
  • Ramjee, M, Henderson, IJ, Sheila McLoughlin, SB & Padova, A (June 2000). "The kinetic and structural characterization of the reaction of nafamostat with bovine pancreatic trypsin". Thrombosis Research. 98 (6): 559–569. doi:10.1016/s0049-3848(00)00206-1. PMID 10899355.{{cite journal}}: نگهداری یادکرد:استفاده از پارامتر نویسندگان (link)
  • Ramjee, M & Patel, S (July 2017). "Continuous-flow injection microfluidic thrombin assays: The effect of binding kinetics on observed enzyme inhibition". Analytical Biochemistry. 528: 38–46. doi:10.1016/j.ab.2017.04.016. PMID 28456636.{{cite journal}}: نگهداری یادکرد:استفاده از پارامتر نویسندگان (link)

ncbi.nlm.nih.gov

  • Al-Horani RA, Desai UR (November 2014). "Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders". Medicinal Research Reviews. 34 (6): 1168–216. doi:10.1002/med.21315. PMC 8788159. PMID 24659483. S2CID 22631056.
  • Chen X, Xu Z, Zeng S, Wang X, Liu W, Qian L, et al. (2019). "The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications". Frontiers in Oncology. 9: 852. doi:10.3389/fonc.2019.00852. PMC 6733886. PMID 31552177.

semanticscholar.org

api.semanticscholar.org

  • Al-Horani RA, Desai UR (November 2014). "Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders". Medicinal Research Reviews. 34 (6): 1168–216. doi:10.1002/med.21315. PMC 8788159. PMID 24659483. S2CID 22631056.